Central to our vision at AbbVie is developing therapies, such as our pan-genotypic HCV treatment, for the most serious diseases and providing access to those treatments. We are pleased to have reached today’s agreement [Licence agreement on hepatitis C treatment glecaprevir/pibrentasvir] with the MPP.
Laura Schumacher, Executive Vice President, External Affairs, General Counsel and Corporate Secretary, AbbVie
The Government of Pakistan warmly welcomes the agreement between the Medicines Patent Pool and AbbVie to expand access to glecaprevir/pibrentasvir – a very important therapy for the treatment of HCV [hepatitis C] – into territories including Pakistan. The HCV burden in Pakistan is endemic, affecting over eight million of our country’s population and the prevention and treatment of HCV is a national priority. This agreement will considerably aid our efforts and, ultimately, accelerate the permanent elimination of the HCV virus.
Mr Aamer Mehmood Kianai, Ministry of National Health Services, Regulations and Coordination, Government of Pakistan
Claiming over one million lives each year, viral hepatitis is one of the world’s major public health challenges and disproportionately affects people living in low- and middle-income countries. Therefore access to safe, quality-assured treatments, affordable for all, has to be the fundamental aim of the public health community. This is a big step in that direction [licence agreement on hepatitis C treatment glecaprevir/pibrentasvir]. The next step is to see more territories included in the agreement. Each step makes the dream of hepatitis C elimination more real.